You are here

Bioavailability Study of Pregabalin Extended Release Formulation With Various Release Rates in Healthy Volunteers

Last updated on May 10, 2018

FOR MORE INFORMATION
Study Location
Pfizer New Haven Clinical Research Unit
New Haven, Connecticut, 06511 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Healthy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Healthy female subjects and/or male subjects who, at the time of screening, are
between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically
relevant abnormalities identified by a detailed medical history, full physical
examination, including blood pressure and pulse rate measurement, 12 lead
electrocardiogram (ECG) or clinical laboratory tests. A 1:1 ratio of men to women is
desirable, but it will not be considered a protocol deviation if this is not met.

2. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).

3. Evidence of a personally signed and dated informed consent document.

4. Subjects who are willing and able to comply with all scheduled visits, treatment plan,
laboratory tests, and other study procedures.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
allergic disease (including drug allergies, but excluding untreated, asymptomatic,
seasonal allergies at the time of dosing).

2. History of febrile illness within 5 days prior to the first dose of study
investigational product.

3. Subjects with an estimated CLcr Gault.1

4. Any condition possibly affecting drug absorption.

5. A positive urine drug screen.

6. Use of tobacco or nicotine containing products in excess of the equivalent of 5
cigarettes per day.

7. History of regular alcohol consumption exceeding 7 drinks/week for females or 14
drinks/week for males (1 drink = 5 ounces [150 mL] of wine or 12 ounces [360 mL] of
beer or 1.5 ounces [45 mL] of hard liquor) within 6 months of Screening.

8. Treatment with an investigational drug within 30 days or 5 half lives preceding the
first dose of study investigational product (whichever is longer).

9. Screening supine blood pressure >= 140 mm Hg (systolic) or >= 90 mm Hg (diastolic),
following at least 5 minutes of supine rest. If blood pressure is >= 140 mm Hg
(systolic) or >= 90 mm Hg (diastolic), the blood pressure should be repeated 2 more
times and the average of the 3 blood pressure values should be used to determine the
subject's eligibility.

10. Screening supine 12 lead ECG demonstrating QTc (time from ECG Q wave to the end of the
T wave corresponding to electrical systole [QT] corrected for the heart rate) >450
msec or a QRS interval (time from ECG Q wave to the end of the S wave corresponding to
ventricle depolarization) >120 msec. If QTc exceeds 450 msec, or QRS exceeds 120 msec,
the ECG should be repeated 2 more times and the average of the 3 QTc or QRS values
should be used to determine the subject's eligibility.

11. Pregnant female subjects; breastfeeding female subjects; male subjects with partners
currently pregnant; male subjects able to father children and female subjects of
childbearing potential who are unwilling or unable to use a highly effective method of
contraception as outlined in this protocol for the duration of the study and for at
least 28 days after the last dose of investigational product.

12. Use of prescription (other than oral, transdermal, intrauterine, implanted, or
injected contraceptives or hormone replacement therapy) or nonprescription drugs and
dietary supplements within 7 days or 5 half lives (whichever is longer) prior to the
first dose of study medication.investigational product. Herbal supplements must be
discontinued at least 28 days prior to the first dose of study
medicationinvestigational product. As an exception, acetaminophen/paracetamol may be
used at doses of greater than 1 g/day. Limited use of non prescription medications
that are not believed to affect subject safety or the overall results of the study may
be permitted on a case by case basis following approval by the Sponsor.

13. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more
within 56 days prior to dosing.

14. History of sensitivity to pregabalin, gabapentin, or other alpha2 delta ligands.

15. History of sensitivity to heparin or heparin induced thrombocytopenia.

16. Unwilling or unable to comply with the Lifestyle Guidelines described in this
protocol.

17. Previous participation in a study involving pregabalin.

18. Subjects who are investigational site staff members directly involved in the study,
their family members, site staff members otherwise supervised by the investigator, or
subjects who are Pfizer employees directly involved in the study.

19. Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation.

NCT02725112
Pfizer
Completed
Bioavailability Study of Pregabalin Extended Release Formulation With Various Release Rates in Healthy Volunteers

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Bioavailability Study of Pregabalin Extended Release Formulation With Various Release Rates in Healthy Volunteers
A Phase 1, Randomized, Open-label, Single-dose, 6-period Study To Investigate The Effect Of In Vitro Dissolution Rate On The In Vivo Bioavailability Of Extended Release Formulations Of Pregabalin In Healthy Volunteers
This study is a Phase 1, randomized, open label, single dose, 6 treatment, 6 period, 6 sequence study in healthy adult volunteers. A total of 24 (4 in each treatment sequence) healthy male and female subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive will be enrolled. Subjects who discontinue from the study may be replaced at the Sponsor's discretion. Screening activities will be completed within approximately 28 days prior to Day 1 of Period 1. Subjects will be randomized to 1 of the 6 treatment sequences as described in Table 1 below. Each treatment sequence will consist of 6 periods with subjects receiving single doses of pregabalin ER 330 mg target release rate tablet, pregabalin ER 330 mg slow release rate tablet, pregabalin ER 330 mg fast release rate tablet, pregabalin IR 300 mg capsule, pregabalin ER 82.5 mg target release rate tablet, and pregabalin ER 330 mg aberrant fast release rate tablet formulations. All study treatments will be administered following a 600- 750 calorie, 30% fat evening meal.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Healthy
  • Drug: Pregabalin ER
    A: Pregabalin ER tablet formulation, Target release rate, 1 x 330 mg, Oral.
  • Drug: Pregabalin ER
    B: Pregabalin ER tablet formulation, Slow release rate, 1 x 330 mg, Oral.
  • Drug: Pregabalin ER
    C: Pregabalin ER tablet formulation, Fast release rate, 1 x 330 mg, Oral.
  • Drug: Pregabalin ER
    D: Pregabalin IR capsule formulation, 1 x 300 mg, Oral.
  • Drug: Pregabalin ER
    E: Pregabalin ER tablet formulation, Target release rate, 1 x 82.5 mg, Oral.
  • Drug: Pregabalin ER
    F: Pregabalin ER tablet formulation, Aberrant fast release rate, 1 x 330 mg, Oral.
  • Experimental: Pregabalin ER- Target Release 330mg
    A: Pregabalin ER tablet formulation, Target release rate, 1 x 330 mg, Oral.
    Intervention: Drug: Pregabalin ER
  • Experimental: Pregabalin ER - Slow Release 330mg
    B: Pregabalin ER tablet formulation, Slow release rate, 1 x 330 mg, Oral.
    Intervention: Drug: Pregabalin ER
  • Experimental: Pregabalin ER - Fast Release 330mg
    C: Pregabalin ER tablet formulation, Fast release rate, 1 x 330 mg, Oral.
    Intervention: Drug: Pregabalin ER
  • Experimental: Pregabalin IR - 300mg
    D: Pregabalin IR capsule formulation, 1 x 300 mg, Oral.
    Intervention: Drug: Pregabalin ER
  • Experimental: Pregabalin ER - Target Release 82.5mg
    E: Pregabalin ER tablet formulation, Target release rate, 1 x 82.5 mg, Oral.
    Intervention: Drug: Pregabalin ER
  • Experimental: Pregabalin ER - Aberrant Fast 330mg
    F: Pregabalin ER tablet formulation, Aberrant fast release rate, 1 x 330 mg, Oral.
    Intervention: Drug: Pregabalin ER
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
June 17, 2016
May 22, 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Healthy female subjects and/or male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead electrocardiogram (ECG) or clinical laboratory tests. A 1:1 ratio of men to women is desirable, but it will not be considered a protocol deviation if this is not met.
  2. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
  3. Evidence of a personally signed and dated informed consent document.
  4. Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

  1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  2. History of febrile illness within 5 days prior to the first dose of study investigational product.
  3. Subjects with an estimated CLcr <60 mL/min derived using the method of Crockcroft and Gault.1
  4. Any condition possibly affecting drug absorption.
  5. A positive urine drug screen.
  6. Use of tobacco or nicotine containing products in excess of the equivalent of 5 cigarettes per day.
  7. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor) within 6 months of Screening.
  8. Treatment with an investigational drug within 30 days or 5 half lives preceding the first dose of study investigational product (whichever is longer).
  9. Screening supine blood pressure >= 140 mm Hg (systolic) or >= 90 mm Hg (diastolic), following at least 5 minutes of supine rest. If blood pressure is >= 140 mm Hg (systolic) or >= 90 mm Hg (diastolic), the blood pressure should be repeated 2 more times and the average of the 3 blood pressure values should be used to determine the subject's eligibility.
  10. Screening supine 12 lead ECG demonstrating QTc (time from ECG Q wave to the end of the T wave corresponding to electrical systole [QT] corrected for the heart rate) >450 msec or a QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization) >120 msec. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTc or QRS values should be used to determine the subject's eligibility.
  11. Pregnant female subjects; breastfeeding female subjects; male subjects with partners currently pregnant; male subjects able to father children and female subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product.
  12. Use of prescription (other than oral, transdermal, intrauterine, implanted, or injected contraceptives or hormone replacement therapy) or nonprescription drugs and dietary supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of study medication.investigational product. Herbal supplements must be discontinued at least 28 days prior to the first dose of study medicationinvestigational product. As an exception, acetaminophen/paracetamol may be used at doses of greater than 1 g/day. Limited use of non prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case by case basis following approval by the Sponsor.
  13. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 56 days prior to dosing.
  14. History of sensitivity to pregabalin, gabapentin, or other alpha2 delta ligands.
  15. History of sensitivity to heparin or heparin induced thrombocytopenia.
  16. Unwilling or unable to comply with the Lifestyle Guidelines described in this protocol.
  17. Previous participation in a study involving pregabalin.
  18. Subjects who are investigational site staff members directly involved in the study, their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees directly involved in the study.
  19. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation.
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT02725112
A0081309
No
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
June 2017

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now